In this study, we used a human breast cancer cell model with endogenous sstr2 expression (ZR-75-1 cells) to compare tumor uptake of the antagonist 68Ga-NODAGA-JR11 with two routinely used agonists 68Ga-DOTATOC and 68Ga-DOTATATE. Here, SSTR2 is linked to breast cancer.